{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:36:39Z","timestamp":1789500999557,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Homologous recombination deficiency (HRD) and sensitivity to PARP inhibitors are key determinants of therapeutic response in high-grade serous ovarian cancer (HGSC), yet predictive biomarkers beyond BRCA1\/2 mutations or genomic HRD scores remain inadequate. Here, we investigate the potential of long non-coding RNAs (lncRNAs) as predictive markers of HRD and PARP inhibitor response. We identify a panel of lncRNAs that stratifies HGSC tumors by HRD status and drug sensitivity. Among these, ENSG00000272172.1 is significantly upregulated in HRD-positive tumors and is detectable in both formalin-fixed tissue and plasma, supporting its use as a minimally invasive biomarker. Functional analyses reveal that this lncRNA contributes to genome stability by modulating replication dynamics. These findings highlight a previously unrecognized role for lncRNAs in the HRD phenotype and suggest translational potential for ENSG00000272172.1 in guiding clinical decision-making.<\/jats:p>","DOI":"10.1038\/s42003-025-08836-9","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:51:35Z","timestamp":1759315895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long non-coding RNAs as a biomarker for homologous recombination deficiency and parp inhibitor sensitivity in high-grade serous ovarian cancers"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9114-9913","authenticated-orcid":false,"given":"Kai","family":"Doberstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Panther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hahnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-5291","authenticated-orcid":false,"given":"Lisa","family":"Richters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Heitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kommoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Berlit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Tuschy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"S\u00fctterlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6591-3367","authenticated-orcid":false,"given":"Frederik","family":"Marm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"8836_CR1","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1002\/ijc.30676","volume":"140","author":"SB Coburn","year":"2017","unstructured":"Coburn, S. B., Bray, F., Sherman, M. E. & Trabert, B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int. J. Cancer 140, 2451\u20132460 (2017).","journal-title":"Int. J. Cancer"},{"key":"8836_CR2","doi-asserted-by":"crossref","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","DOI":"10.3322\/caac.21660"},{"key":"8836_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/1055-9965.EPI-16-0858","volume":"26","author":"LA Torre","year":"2017","unstructured":"Torre, L. A., Islami, F., Siegel, R. L., Ward, E. M. & Jemal, A. Global cancer in women: burden and trends. Cancer Epidemiol. Biomark. Prev. 26, 444\u2013457 (2017).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"8836_CR4","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.mam.2013.01.006","volume":"34","author":"NJ Curtin","year":"2013","unstructured":"Curtin, N. J. & Szabo, C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol. Asp. Med. 34, 1217\u20131256 (2013).","journal-title":"Mol. Asp. Med."},{"key":"8836_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin, N. J. & Szabo, C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat. Rev. Drug Discov. 19, 711\u2013736 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"8836_CR6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005).","journal-title":"Nature"},{"key":"8836_CR7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"8836_CR8","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","volume":"30","author":"J Mateo","year":"2019","unstructured":"Mateo, J. et al. A decade of clinical development of PARP inhibitors in perspective. Ann. Oncol. 30, 1437\u20131447 (2019).","journal-title":"Ann. Oncol."},{"key":"8836_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615 (2011).","journal-title":"Nature"},{"key":"8836_CR10","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai, J. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72, 5588\u20135599 (2012).","journal-title":"Cancer Res"},{"key":"8836_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.molcel.2018.06.004","volume":"71","author":"H Hanzlikova","year":"2018","unstructured":"Hanzlikova, H. et al. The importance of Poly(ADP-Ribose) polymerase as a sensor of unligated Okazaki fragments during DNA replication. Mol. Cell 71, 319\u2013331.e3 (2018).","journal-title":"Mol. Cell"},{"key":"8836_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19406-4","volume":"11","author":"L Nguyen","year":"2020","unstructured":"Nguyen, L., Martens, W. M. J., Van Hoeck, A. & Cuppen, E. Pan-cancer landscape of homologous recombination deficiency. Nat. Commun. 11, 5584 (2020).","journal-title":"Nat. Commun."},{"key":"8836_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrg.2015.10","volume":"17","author":"JJ Quinn","year":"2016","unstructured":"Quinn, J. J. & Chang, H. Y. Unique features of long non-coding RNA biogenesis and function. Nat. Rev. Genet. 17, 47\u201362 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"8836_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","volume":"22","author":"L Statello","year":"2021","unstructured":"Statello, L., Guo, C.-J., Chen, L.-L. & Huarte, M. Gene regulation by long non-coding RNAs and its biological functions. Nat. Rev. Mol. Cell Biol. 22, 96\u2013118 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"8836_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cell.2011.09.028","volume":"147","author":"M Cesana","year":"2011","unstructured":"Cesana, M. et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 147, 358\u2013369 (2011).","journal-title":"Cell"},{"key":"8836_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/nature09144","volume":"465","author":"L Poliseno","year":"2010","unstructured":"Poliseno, L. et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465, 1033\u20131038 (2010).","journal-title":"Nature"},{"key":"8836_CR17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nature12943","volume":"505","author":"A Necsulea","year":"2014","unstructured":"Necsulea, A. et al. The evolution of lncRNA repertoires and expression patterns in tetrapods. Nature 505, 635\u2013640 (2014).","journal-title":"Nature"},{"key":"8836_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nature07672","volume":"458","author":"M Guttman","year":"2009","unstructured":"Guttman, M. et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458, 223\u2013227 (2009).","journal-title":"Nature"},{"key":"8836_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cell.2010.06.040","volume":"142","author":"M Huarte","year":"2010","unstructured":"Huarte, M. et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142, 409\u2013419 (2010).","journal-title":"Cell"},{"key":"8836_CR20","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08975","volume":"464","author":"RA Gupta","year":"2010","unstructured":"Gupta, R. A. et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071\u20131076 (2010).","journal-title":"Nature"},{"key":"8836_CR21","first-page":"296","volume":"5","author":"D Amit","year":"2012","unstructured":"Amit, D. & Hochberg, A. Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. Int. J. Clin. Exp. Med. 5, 296\u2013305 (2012).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"8836_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-69","volume":"7","author":"A Mizrahi","year":"2009","unstructured":"Mizrahi, A. et al. Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. J. Transl. Med. 7, 69 (2009).","journal-title":"J. Transl. Med."},{"key":"8836_CR23","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1101\/gad.17446611","volume":"25","author":"MN Cabili","year":"2011","unstructured":"Cabili, M. N. et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 25, 1915\u20131927 (2011).","journal-title":"Genes Dev."},{"key":"8836_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature11233","volume":"489","author":"S Djebali","year":"2012","unstructured":"Djebali, S. et al. Landscape of transcription in human cells. Nature 489, 101\u2013108 (2012).","journal-title":"Nature"},{"key":"8836_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nature21374","volume":"543","author":"C-C Hon","year":"2017","unstructured":"Hon, C.-C. et al. An atlas of human long non-coding RNAs with accurate 5\u2019 ends. Nature 543, 199\u2013204 (2017).","journal-title":"Nature"},{"key":"8836_CR26","doi-asserted-by":"publisher","unstructured":"De Goede, O. M. et al. Population-scale tissue transcriptomics maps long non-coding RNAs to complex disease. Cell https:\/\/doi.org\/10.1016\/j.cell.2021.03.050. (2021).","DOI":"10.1016\/j.cell.2021.03.050"},{"key":"8836_CR27","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.tranon.2018.07.016","volume":"11","author":"Y Lin","year":"2018","unstructured":"Lin, Y., Leng, Q., Zhan, M. & Jiang, F. A plasma long noncoding RNA signature for early detection of lung cancer. Transl. Oncol. 11, 1225\u20131231 (2018).","journal-title":"Transl. Oncol."},{"key":"8836_CR28","first-page":"62","volume":"6","author":"Z Gu","year":"2020","unstructured":"Gu, Z., Shen, H.-Q., Fu, P.-H. & Chen, M. Screening of long non-coding RNAs markers in plasma of children with chronic gastritis. Chronic Dis. Transl. Med. 6, 62\u201368 (2020).","journal-title":"Chronic Dis. Transl. Med."},{"key":"8836_CR29","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1159\/000493613","volume":"49","author":"J Shi","year":"2018","unstructured":"Shi, J. et al. The plasma lncRNA acting as fingerprint in hilar cholangiocarcinoma. Cell. Physiol. Biochem. 49, 1694\u20131702 (2018).","journal-title":"Cell. Physiol. Biochem."},{"key":"8836_CR30","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1159\/000495961","volume":"51","author":"D Hu","year":"2018","unstructured":"Hu, D. et al. Plasma exosomal long non-coding RNAs serve as biomarkers for early detection of colorectal cancer. Cell. Physiol. Biochem. 51, 2704\u20132715 (2018).","journal-title":"Cell. Physiol. Biochem."},{"key":"8836_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00283-7","volume":"6","author":"C Badowski","year":"2022","unstructured":"Badowski, C., He, B. & Garmire, L. X. Blood-derived lncRNAs as biomarkers for cancer diagnosis: the Good, the Bad and the Beauty. NPJ Precis. Oncol. 6, 40 (2022).","journal-title":"NPJ Precis. Oncol."},{"key":"8836_CR32","doi-asserted-by":"publisher","first-page":"8031","DOI":"10.1038\/sj.onc.1206928","volume":"22","author":"P Ji","year":"2003","unstructured":"Ji, P. et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22, 8031\u20138041 (2003).","journal-title":"Oncogene"},{"key":"8836_CR33","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1515\/cclm-2012-0392","volume":"51","author":"AF Neves","year":"2013","unstructured":"Neves, A. F., Dias-Oliveira, J. D. D., Ara\u00fajo, T. G., Marangoni, K. & Goulart, L. R. Prostate cancer antigen 3 (PCA3) RNA detection in blood and tissue samples for prostate cancer diagnosis. Clin. Chem. Lab. Med. 51, 881\u2013887 (2013).","journal-title":"Clin. Chem. Lab. Med."},{"key":"8836_CR34","first-page":"94","volume":"2016","author":"MT Zimmermann","year":"2016","unstructured":"Zimmermann, M. T., Jiang, G. & Wang, C. Single-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer Patients. AMIA Jt Summits Transl. Sci. Proc. 2016, 94\u2013100 (2016).","journal-title":"AMIA Jt Summits Transl. Sci. Proc."},{"key":"8836_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10549-012-2188-0","volume":"135","author":"A Daemen","year":"2012","unstructured":"Daemen, A. et al. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res. Treat. 135, 505\u2013517 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"8836_CR36","doi-asserted-by":"publisher","first-page":"19489","DOI":"10.1073\/pnas.1314302110","volume":"110","author":"D Etemadmoghadam","year":"2013","unstructured":"Etemadmoghadam, D. et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc. Natl. Acad. Sci. USA 110, 19489\u201319494 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"8836_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-017-0025-7","volume":"3","author":"DM Wolf","year":"2017","unstructured":"Wolf, D. M. et al. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib\/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer 3, 31 (2017).","journal-title":"NPJ Breast Cancer"},{"key":"8836_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-024-03018-4","volume":"11","author":"S Takamatsu","year":"2024","unstructured":"Takamatsu, S., Murakami, K. & Matsumura, N. Homologous recombination deficiency unrelated to platinum and PARP inhibitor response in cell line libraries. Sci. Data 11, 171 (2024).","journal-title":"Sci. Data"},{"key":"8836_CR39","doi-asserted-by":"publisher","first-page":"6559","DOI":"10.1158\/1078-0432.CCR-21-1673","volume":"27","author":"PC Schouten","year":"2021","unstructured":"Schouten, P. C. et al. Ovarian cancer-specific BRCA-like copy-number aberration classifiers detect mutations associated with homologous recombination deficiency in the AGO-TR1 trial. Clin. Cancer Res. 27, 6559\u20136569 (2021).","journal-title":"Clin. Cancer Res."},{"key":"8836_CR40","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli, M. L. et al. Homologous Recombination Deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin. Cancer Res. 22, 3764\u20133773 (2016).","journal-title":"Clin. Cancer Res."},{"key":"8836_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0475-x","volume":"16","author":"KM Timms","year":"2014","unstructured":"Timms, K. M. et al. Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 16, 475 (2014).","journal-title":"Breast Cancer Res."},{"key":"8836_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-015-0033-4","volume":"3","author":"AM Marquard","year":"2015","unstructured":"Marquard, A. M. et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark. Res. 3, 9 (2015).","journal-title":"Biomark. Res."},{"key":"8836_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00388-9","volume":"8","author":"KN Maxwell","year":"2017","unstructured":"Maxwell, K. N. et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat. Commun. 8, 319 (2017).","journal-title":"Nat. Commun."},{"key":"8836_CR44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","volume":"559","author":"A Maya-Mendoza","year":"2018","unstructured":"Maya-Mendoza, A. et al. High speed of fork progression induces DNA replication stress and genomic instability. Nature 559, 279\u2013284 (2018).","journal-title":"Nature"},{"key":"8836_CR45","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","volume":"71","author":"AD D\u2019Andrea","year":"2018","unstructured":"D\u2019Andrea, A. D. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair 71, 172\u2013176 (2018).","journal-title":"DNA Repair"},{"key":"8836_CR46","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017).","journal-title":"Science"},{"key":"8836_CR47","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/gcc.22935","volume":"60","author":"T Foo","year":"2021","unstructured":"Foo, T., George, A. & Banerjee, S. PARP inhibitors in ovarian cancer: an overview of the practice-changing trials. Genes Chromosomes Cancer 60, 385\u2013397 (2021).","journal-title":"Genes Chromosomes Cancer"},{"key":"8836_CR48","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391\u20132402 (2019).","journal-title":"N. Engl. J. Med."},{"key":"8836_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41416-021-01295-z","volume":"125","author":"P-M Morice","year":"2021","unstructured":"Morice, P.-M. et al. Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays. Br. J. Cancer 125, 7\u201314 (2021).","journal-title":"Br. J. Cancer"},{"key":"8836_CR50","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/jnci\/djy085","volume":"110","author":"MM Hoppe","year":"2018","unstructured":"Hoppe, M. M., Sundar, R., Tan, D. S. P. & Jeyasekharan, A. D. Biomarkers for homologous recombination deficiency in cancer. J. Natl Cancer Inst. 110, 704\u2013713 (2018).","journal-title":"J. Natl Cancer Inst."},{"key":"8836_CR51","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41571-020-0335-9","volume":"17","author":"SN Banerjee","year":"2020","unstructured":"Banerjee, S. N. & Lord, C. J. First-line PARP inhibition in ovarian cancer - standard of care for all?. Nat. Rev. Clin. Oncol. 17, 136\u2013137 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"8836_CR52","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"8836_CR53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41420-021-00560-7","volume":"7","author":"W Ma","year":"2021","unstructured":"Ma, W. et al. Identification of a seven-long non-coding RNA signature associated with Jab1\/CSN5 in predicting hepatocellular carcinoma. Cell Death Discov. 7, 178 (2021).","journal-title":"Cell Death Discov."},{"key":"8836_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01401-x","volume":"8","author":"T Moiseeva","year":"2017","unstructured":"Moiseeva, T. et al. ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1. Nat. Commun. 8, 1392 (2017).","journal-title":"Nat. Commun."},{"key":"8836_CR55","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1101\/gad.457807","volume":"21","author":"XQ Ge","year":"2007","unstructured":"Ge, X. Q., Jackson, D. A. & Blow, J. J. Dormant origins licensed by excess Mcm2-7 are required for human cells to survive replicative stress. Genes Dev. 21, 3331\u20133341 (2007).","journal-title":"Genes Dev."},{"key":"8836_CR56","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.1073\/pnas.0803978105","volume":"105","author":"A Ibarra","year":"2008","unstructured":"Ibarra, A., Schwob, E. & M\u00e9ndez, J. Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication. Proc. Natl. Acad. Sci. USA 105, 8956\u20138961 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"8836_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2015.12.017","volume":"164","author":"S Lee","year":"2016","unstructured":"Lee, S. et al. Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins. Cell 164, 69\u201380 (2016).","journal-title":"Cell"},{"key":"8836_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01382-y","volume":"20","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. Long non-coding RNA ANRIL promotes homologous recombination-mediated DNA repair by maintaining ATR protein stability to enhance cancer resistance. Mol. Cancer 20, 94 (2021).","journal-title":"Mol. Cancer"},{"key":"8836_CR59","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13046-023-02829-4","volume":"42","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. ATR-binding lncRNA ScaRNA2 promotes cancer resistance through facilitating efficient DNA end resection during homologous recombination repair. J. Exp. Clin. Cancer Res. 42, 256 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"8836_CR60","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/0008-5472.CAN-13-3159","volume":"74","author":"JR Prensner","year":"2014","unstructured":"Prensner, J. R. et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 74, 1651\u20131660 (2014).","journal-title":"Cancer Res."},{"key":"8836_CR61","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.15252\/embr.201540437","volume":"16","author":"V Sharma","year":"2015","unstructured":"Sharma, V. et al. A BRCA1-interacting lncRNA regulates homologous recombination. EMBO Rep. 16, 1520\u20131534 (2015).","journal-title":"EMBO Rep."},{"key":"8836_CR62","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.7150\/jca.91896","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu, Y. & Liu, G. Targeting NEAT1 affects the sensitivity to parpi in serous ovarian cancer by regulating the homologous recombination repair pathway. J. Cancer 15, 1397\u20131413 (2024).","journal-title":"J. Cancer"},{"key":"8836_CR63","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675\u2013678 (2020).","journal-title":"Nat. Biotechnol."},{"key":"8836_CR64","doi-asserted-by":"crossref","unstructured":"Cancer Cell Line Encyclopedia Consortium & Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement between two cancer cell line data sets. Nature 528, 84\u201387 (2015).","DOI":"10.1038\/nature15736"},{"key":"8836_CR65","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1158\/0008-5472.CAN-15-0273","volume":"75","author":"J Li","year":"2015","unstructured":"Li, J. et al. TANRIC: an interactive open platform to explore the function of lncRNAs in cancer. Cancer Res. 75, 3728\u20133737 (2015).","journal-title":"Cancer Res."},{"key":"8836_CR66","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","volume":"23","author":"TA Knijnenburg","year":"2018","unstructured":"Knijnenburg, T. A. et al. Genomic and molecular landscape of DNA damage repair deficiency across the Cancer Genome Atlas. Cell Rep. 23, 239\u2013254.e6 (2018).","journal-title":"Cell Rep."},{"key":"8836_CR67","doi-asserted-by":"publisher","first-page":"e2100159","DOI":"10.1200\/PO.21.00159","volume":"6","author":"AA Kraya","year":"2022","unstructured":"Kraya, A. A. et al. PTEN loss and BRCA1 promoter hypermethylation negatively predict for immunogenicity in BRCA-deficient ovarian cancer. JCO Precis. Oncol. 6, e2100159 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"8836_CR68","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"8836_CR69","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-13-2247","volume":"74","author":"AM Karst","year":"2014","unstructured":"Karst, A. M. et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 74, 1141\u20131152 (2014).","journal-title":"Cancer Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08836-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08836-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08836-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:04:02Z","timestamp":1759320242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08836-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8836"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-08836-9","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.H. declares affiliations in various capacities with AstraZeneca, Roche, Tesaro, GSK, Clovis, amedes, ZaiLab, MSD, Immunogen, and AbbVie. P.C.S. declares employment by an AstraZeneca partner, as well as engagement in contract pathology work unrelated to the topic of the paper. Additionally, P.C.S. is a named inventor on the patent application \u201cMethods for assessing homologous recombination deficiency in ovarian cancer cells\u201d (WO2023031121, international publication date: March 9, 2023). P.L. is a shareholder and co-founder of VUS diagnostics BV (trading name VUS Genetics), unrelated to this work. L.R. received a travel accommodation grant from AstraZeneca in 2024.\u00a0These disclosures do not influence the objectivity or conclusions of this work. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1410"}}